Table 1.
Biomechanical competence of bones (strength) of animals treated with sclerostin antibody
| Animal | Age | Treatment | Duration | Strength | Ref. |
|---|---|---|---|---|---|
| Intact gonads | |||||
| Rats (M) | 6 month | Scl-AbVI 2/week | 9 week | ↑F, V(nd) | [64] |
| Rats (M) | 7 month | Scl-AbIII 2/week | 7 week | ↑V/F | [46] |
| Rats (M) | 16 month | Scl-AbII 2/week | 5 week | ↑V/F | [37] |
| Cynos (Fe) | 3–5 years | Scl-AbIV 1/month | 2 week | ↑V↔F | [49] |
| Cynos (M) | 4–5 years | Scl-AbV 2/week | 10 week | ↑V/F | [46] |
| Estrogen deficiency (OVX) | |||||
| Rats | 18 montha | Scl-AbII 2/week | 5 week | ↑V/F | [34] |
| Rats | 6 monthb | Scl-AbVI 1/wh | 26 week | ↑V/F | [50] |
| Rats | 6.5 monthc | Scl-A III 1/week | 6 week | ↑V, F(nd) | [35] |
| Cynos | ≥9 years | ROMO 1/weekd | 12 month | ↑V/F | [65] |
Cynos cynomolgus monkeys, Scl-Ab sclerostin antibody, ROMO romosozumab, V vertebra, F femur, nd not examined
aOVX at 6 months
bOVX at 4 months
cOVX at 3.5 month
dStart treatment 4 month after OVX